RGENRGENHealthcare · Medical Instruments & Supplies

RGEN Stock Forecast: Repligen Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$164
−3.76% on the day

The 20 Wall Street analysts covering Repligen Corp. hold a median 12-month price target of $200 — +22.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 87 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$10.5B
Ticker Nerd rank
87/ 100
Median analyst target
$200
Analysts covering
20
Revenue$204.1M+11.9% y/y
Operating income$19.0M
Net income$5.0M
Free cash flow$26.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.3%
1M
−8.4%
YTD
+0.0%
1Y
+6.2%
From 52W high
−15.8%
From 52W low
+59.3%
$103
$195
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Repligen Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
87/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
83
Volatility
80
Revisions
78
Accruals
77
Momentum
76
Value
72
Growth
65
Issuance
52

Quality (83): The business earns solid, repeatable profits on what it owns.

Issuance (52): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250Jan 26Apr 26Jul 26Oct 26RGENHigh $235Median $200Low $175

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts
16
Buy
4
Hold
0
Sell
$175
Low
$200
Median
$235
High

The green dot is the last close — the median target sits +22.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
28 Oct 2026RBC CapitalMaintainsOutperform$185 → $200
19 Oct 2026Canaccord GenuityMaintainsHold$145 → $180
7 Oct 2026BarclaysMaintainsOverweight$175 → $225
9 Sept 2026UBSMaintainsBuy$195 → $225
30 July 2026Wells FargoMaintainsOverweight$180 → $185
29 July 2026JP MorganMaintainsOverweight$165 → $175
7 July 2026BenchmarkUpgradeBuy$185
6 July 2026Evercore ISI GroupMaintainsOutperform$150 → $160
3 June 2026HSBCMaintainsBuy—
2 June 2026Wolfe ResearchAssumesOutperform$145
15 May 2026RBC CapitalReinstatesOutperform$160
6 May 2026BarclaysMaintainsOverweight—
6 May 2026JP MorganMaintainsOverweight—
20 Apr 2026Canaccord GenuityMaintainsHold—
17 Apr 2026Roth CapitalInitiatesBuy—
14 Apr 2026BarclaysMaintainsOverweight—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Feb 2026BarclaysMaintainsOverweight—
25 Feb 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RGEN.

Market Radar

This page is one stock. Monday covers all of them.

RGEN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Repligen Corp. returned +6.2% against +6.9% for the S&P 500, dividends included.

RGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120130Jan 26Apr 26Jul 26Oct 26RGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+0.4%
Analysts raising
8
Analysts cutting
5
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
13.0×

Cheaper than 10% of US stocks

Price / book
4.4×

Cheaper than 21% of US stocks

EV / EBITDA
71.8×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
10.9%

Higher than 56% of US stocks

Earnings growth (YoY)
—
Gross margin
53.9%

Higher than 66% of US stocks

Operating margin
8.1%

Higher than 60% of US stocks

Net margin
—
Returns & dividend
Return on equity
−0.6%

Higher than 44% of US stocks

Return on assets
1.4%

Higher than 53% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Repligen Corp. has a market value of $10.5B and an enterprise value of $10.3B.

  • Revenue in the twelve months to 30 June 2026: $785.1M. The latest quarter grew 11.9% year on year.

  • Net income over the same four quarters: $41.5M, a 5.3% net margin.

  • Diluted earnings per share, trailing twelve months: $0.73.

  • Free cash flow in the twelve months to 30 June 2026: $110.2M, after $1.8M of capital spending.

  • Shares outstanding: 56.4M.

  • forward P/E: 61.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Repligen Corp. employs 2,000 people — $393K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

RGEN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
RGENRepligen Corp.$10.5B87
AVTRAvantor, Inc.$10.1B83
ALGNAlign Technology, Inc.$11.1B83
COOThe Cooper Cos., Inc.$11.5B71
ATRAptarGroup, Inc.$9.2B62
BAXBaxter International, Inc.$13.1B94
SOLVSolventum Corp.$14.7B76

Take a look at RGEN’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Repligen Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RGEN

What is the RGEN stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Repligen Corp. have a median 12-month price target of $200, with estimates ranging from $175 to $235. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RGEN stock a buy right now?

Of the 20 analysts covering Repligen Corp., 16 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Repligen Corp. 87 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RGEN?

As at 21 Nov 2026, Repligen Corp. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (83 of 100).

Will RGEN stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +22.0% from the last close, and Ticker Nerd's factor model ranks Repligen Corp. 87 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RGEN stock forecast for 2030?

No analyst covering Repligen Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $175 to $235 over the next 12 months.

How has RGEN stock performed over the past year?

Repligen Corp. returned +6.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Repligen Corp. do?

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biologic drugs. Repligen Corporation’s portfolio supports both upstream and downstream workflows across filtration, fluid management, chromatography, process analytics, and single-use technologies.

Company

About Repligen Corp.

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biologic drugs. Repligen Corporation’s portfolio supports both upstream and downstream workflows across filtration, fluid management, chromatography, process analytics, and single-use technologies. Its products are used by biopharmaceutical companies and contract development and manufacturing organizations to improve efficiency, control, and consistency in production processes. The company offers consumables and instruments such as Protein A ligands, chromatography columns, filtration systems, and analytical tools designed for biologics processing. Headquartered in Waltham, Massachusetts, Repligen Corporation serves customers across North America, Europe, the Asia Pacific, and other international markets, making it an important supplier within the bioprocessing and life sciences tools sector.

CEO Mr. Olivier Loeillot · 2,000 employees · United States · https://www.repligen.com